Pipeline

Project
Indication
Target
Approach
Screening
Pre-Clinical
IND
Phase I
Phase II
Phase III
ZV0203
Breast Cancer
HER2++
FIC

Project:ZV0203

Indication:Breast Cancer

Target:HER2++

Approach:FIC

Screening
Pre-Clinical
IND
Phase I
Phase II
Phase III
learn more learn more
ACR246
Solid Tumors
5T4
BIC

Project:ACR246

Indication:Solid Tumors

Target:5T4

Approach:BIC

Screening
Pre-Clinical
IND
Phase I
Phase II
Phase III
learn more learn more
ADC2204
Solid Tumors
Nectin-4
FIC/FIG,Co-development

Project:ADC2204

Indication:Solid Tumors

Target:Nectin-4

Approach:FIC/FIG,Co-development

Screening
Pre-Clinical
IND
Phase I
Phase II
Phase III
learn more learn more
ADC2202
Breast Cancer
HER2-low
FIG (Dual payload)

Project:ADC2202

Indication:Breast Cancer

Target:HER2-low

Approach:FIG (Dual payload)

Screening
Pre-Clinical
IND
Phase I
Phase II
Phase III
learn more learn more
ADC2192
Solid Tumors
Trop2
FIG (Dual payload)

Project:ADC2192

Indication:Solid Tumors

Target:Trop2

Approach:FIG (Dual payload)

Screening
Pre-Clinical
IND
Phase I
Phase II
Phase III
learn more learn more
ADC2313
Solid Tumors
cMet/EGFR
FIG (Bispecific)

Project:ADC2313

Indication:Solid Tumors

Target:cMet/EGFR

Approach:FIG (Bispecific)

Screening
Pre-Clinical
IND
Phase I
Phase II
Phase III
ADC2336
Ovarian
Undisclosed
FIC/BIC

Project:ADC2336

Indication:Ovarian

Target:Undisclosed

Approach:FIC/BIC

Screening
Pre-Clinical
IND
Phase I
Phase II
Phase III
ADC2317
Colorectal Cancer
Undisclosed
FIC

Project:ADC2317

Indication:Colorectal Cancer

Target:Undisclosed

Approach:FIC

Screening
Pre-Clinical
IND
Phase I
Phase II
Phase III
ADC2403
Sarcoma,liver cancer
Undisclosed
FIC

Project:ADC2403

Indication:Sarcoma,liver cancer

Target:Undisclosed

Approach:FIC

Screening
Pre-Clinical
IND
Phase I
Phase II
Phase III
ZV0203

ADC2122(ZV0203)is a FIC pertuzumab ADC in clinical development, which has a pertuzumab/Perjeta biosimilar antibody, a microtubule inhibitor DUO-5 (a Dolastatin 10 derivative), a proteolytically cleavable valine-citruline dipeptide linker, with antibody-to-drug ratio (DAR) of 2. Pertuzumab is different from trastuzumab in that it binds to HER2 domain II, instead of IV for trastuzumab, and block not only homodimerization of HER2 itself, but also HER2 and EGFR, HER2 and HER3, HER2 and HER4 heterodimerization. Currently ADC2122 has completed Phase I dose titration with no DLT (Dose Limiting Toxicity), SAE (Serious Adverse Event) or SUSAR (Suspected Unexpected Serious Adverse Reaction) incidence with significant antitumor effects at both doses of 2.7mg/kg and 3.6mg/kg.

ACR246

 ACR246, a best-in-class and potentially first-to-launch ADC product, targeting 5T4 oncofetal antigen with a proprietary topoisomerase I inhibitor, has been greenlit for clinical trials in China in January 2024, with FIH trials set to launch in the 1st quarter of 2024. ACR246 standing at the forefront of oncological innovation, is designed with a stable and tumor microenvironment (TME)-cleavable linker, and has demonstrated substantial anti-tumor activity, safety, pharmacokinetics, and tolerability in preclinical studies involving rodent and non-human primate models. The specificity of 5T4, predominantly expressed in various solid tumors and minimally in normal adult tissues, underscores ACR246's potential in a broad spectrum of oncological applications, and heralds a new era in precision oncology. 

ADC2204

ADC2204 is a new generation Nectin-4 targeting ADC, which is being co-developed in collaboration with Lunan Pharmaceuticals. It has demonstrated superior safety, efficacy and tolerability compared to PADCEV® in a panel of CDX models.

ADC2202

ADC2202 is a dual payload ADC setting up the new criteria of 3rd generation HER2 ADC. It is developed with MuSC™, which contains two types of drugs of different MOA that have synergistic effects in disrupting cell organelle. It is being evaluated preclinically with DS-8201 head-to-head comparison. Initial data has demonstrated potent antitumor effects and a far superior efficacy compared to DS-8201 in several CDX models.

ADC2192

ADC2192 is a Trop2 targeting dual drug ADC developed based on MuSC™ platform, which consists of two types of payloads with different MOA to promote synergistic effects. It is being evaluated preclinically with a marketed and/or more advanced in development candidate head-to-head comparison. Initial data has already shown excellent synergistic effects and superior efficacy compared to the reference in several CDX models.

For more information,please contact us at BD@adcoris.com.cn